Purine inhibitors of fructose 1,6-bisphosphatase

US6284748A · kind A · utility

Assignee

• Metabasis Therapeutics, Inc. · US

Inventors

• Qun Dang · Westfield, US
• Mark D. Erion · Del Mar, US
• M. Rami Reddy · San Diego, US
• Edward D. Robinson · San Diego, US
• Srinivas Rao Kasibhatla · San Diego, US
• K. Raja Reddy · San Diego, US

Key dates

• Filing date: Mar 6, 1998
• Grant date: Sep 4, 2001
• Expiry date: Mar 6, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/657181
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel purine compounds of the following structure and their use as fructose-1,6-bisphosphatase inhibitors is described. ##STR1## wherein PA1 A is selected from the group consisting of --NR.sup.8.sub.2, --NHSO.sub.2 R.sup.3, --OR.sup.5, --SR.sup.5, halo, lower alkyl, --CON(R.sup.4).sub.2, guanidino, amidino, --H, and perhaloalkyl; PA1 E is selected from the group consisting of --H, halo, lower alkylthio, lower perhaloalkyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, --CN, and --NR.sup.7.sub.2 ; PA1 X is selected from the group consisting of -alk-NR--, alkylene, alkenylene, alkynylene, arylene, heteroarylene, -alk-NR-alk-, -alk-O-alk-, -alk-S-alk-, -alk-S--, alicyclicene, heteroalicyclicene, 1,1-dihaloalkylene, --C(O)-alk-, --NR--C(O)--NR'--, -alk-NR--C(O)--, -alk-C(O)--NR--, --Ar-alk-, and -alk-Ar--, all optionally substituted, wherein each R and R' is independently selected from --H and lower alkyl, and wherein each "alk" and "Ar" is an independently selected alkylene or arylene, respectively; PA1 Y is selected from the group consisting of --H, alkyl, alkenyl, alkynyl, aryl, alicyclic, heteroalicyclic, aralkyl, aryloxyalkyl, alkoxyalkyl, --C(O)R.sup.3, --S(O).sub.2 R.…